Stewart Cole

Related publications (489)

About
Privacy
Disclaimer

Related publications (489)

Cross-Resistance between Clofazimine and Bedaquiline through Upregulation of MmpL5 in Mycobacterium tuberculosis

Stewart Cole, Ruben Hartkoorn, Swapna Uplekar

The antileprosy drug clofazimine is also of interest for the treatment of multidrug-resistant tuberculosis. To understand possible resistance mechanisms, clofazimine-resistant Mycobacterium tuberculosis mutants were isolated in vitro, and, unexpectedly, fo ...

Amer Soc Microbiology2014

The cysteine desulfurase IscS of Mycobacterium tuberculosis is involved in iron sulfur cluster biogenesis and oxidative stress defence

Stewart Cole, Florence Pojer, Gaëlle Séraphine Kolly, Jan Lars Rybniker, Jeffrey Chen

The complex multiprotein systems for the assembly of protein-bound iron sulfur (Fe S) clusters are well defined in Gram-negative model organisms. However, little is known about Fe S cluster biogenesis in other bacterial species. The ISC (iron sulfur cluste ...

Portland Press2014

The Phosphatidyl-myo-Inositol Mannosyltransferase PimA Is Essential for Mycobacterium tuberculosis Growth In Vitro and In Vivo

Stewart Cole, Neeraj Dhar, Claudia Sala, Ming Zhang, Gaëlle Séraphine Kolly, Naveen Kumar

The cell envelope of Mycobacterium tuberculosis contains glycans and lipids of peculiar structure that play prominent roles in the biology and pathogenesis of tuberculosis. Consequently, the chemical structure and biosynthesis of the cell wall have been in ...

Amer Soc Microbiology2014

Assessing essentiality of transketolase in Mycobacterium tuberculosis using an inducible protein degradation system

Stewart Cole, Claudia Sala, Anthony Vocat, Gaëlle Séraphine Kolly

Improved genetic tools are required to identify new drug targets in Mycobacterium tuberculosis. To this aim, genetic approaches, targeting either transcription and/or protein degradation, have been developed to appraise gene essentiality and to test the im ...

Wiley-Blackwell2014

EspI regulates the ESX-1 secretion system in response to ATP levels in Mycobacterium tuberculosis

Stewart Cole, Neeraj Dhar, Claudia Sala, Ming Zhang, Jan Lars Rybniker, Jeffrey Chen

The function of EspI, a 70kDa protein in Mycobacterium tuberculosis, has remained unclear. Although EspI is encoded by a gene within the esx-1 locus, in this study we clarify previous conflicting results and show that EspI is not essential for ESX-1-mediat ...

Wiley-Blackwell2014

Genome-wide re-sequencing of multidrug-resistant Mycobacterium leprae Airaku-3

Stewart Cole, Jacques Rougemont, Andrej Benjak, Charlotte Avanzi, Philippe Busso, Pushpendra Singh

Genotyping and molecular characterization of drug resistance mechanisms in Mycobacterium leprae enables disease transmission and drug resistance trends to be monitored. In the present study, we performed genome-wide analysis of Airaku-3, a multidrug-resist ...

Wiley-Blackwell2014

Tuberculosis drug discovery in the post-post-genomic era

Stewart Cole, Jan Lars Rybniker, Benoit Lechartier

The expectation that genomics would result in new therapeutic interventions for infectious diseases remains unfulfilled. In the post-genomic era, the decade immediately following the availability of the genome sequence of Mycobacterium tuberculosis, tuberc ...

Wiley Open Access2014

Background: Leprosy has afflicted humankind throughout history leaving evidence in both early texts and the archaeological record. In Britain, leprosy was widespread throughout the Middle Ages until its gradual and unexplained decline between the 14th and ...

Biomed Central Ltd2014

, ,

Among the few proteins shown to be secreted by the Tat system in Mycobacterium tuberculosis, Rv2525c is of particular interest, since its gene is conserved in the minimal genome of Mycobacterium leprae. Previous evidence linked this protein to cell wall me ...

Elsevier2014

New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects

Stewart Cole

About 1.3 million people died of tuberculosis in 2012, despite availability of effective drug treatment. Barriers to improvements in outcomes include long treatment duration (resulting in poor patient adherence and loss of patients to follow-up), complex r ...

Elsevier Science Inc2014

Page 10 of 49